OptimizeRx Corporation (NASDAQ:OPRX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
William Febbo - Chief Executive Officer
Ed Stelmakh - Chief Financial Officer & Chief Operating Officer
Andrew D’Silva - Senior Vice President of Corporate Finance
Conference Call Participants
Ryan Daniels - William Blair
Sean Dodge - RBC Capital Markets
Mark Wiesenberger - B. Riley Securities
Max Michaelis - Lake Street Capital Markets
Harvey Poppel - Poppel
Operator
Greetings. Welcome to OptimizeRx Corporation's First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to Will Febbo. Thank you. You may begin.
William Febbo
Thank you, operator. Hi, everyone. Good afternoon, and thank you for joining OptimizeRx for our first call of the new fiscal year. Our mission remains to stay ahead of Healthcare's rapidly evolving digital transformation, building a more informed and empowered health care community by developing new technology solutions that help people start and stay on life-impacting therapies.
In executing our operating strategy, we have the privilege of serving doctors and patients at the point of care, but also enabling our pharma clients digital engagement and connectivity at a time when the need could not be greater.
Our technology solutions and market-leading HCP network are a pragmatic choice for our clients who are looking for strong digital connection to their end markets. The technology platform that we have built is incredibly powerful, especially when married with a large health care provider network.
The connectivity we have to point of care is very valuable to our clients, doctors and patients as the epicenter of care delivery and digital enablement. We are seeing more and more conversations with our clients and network partners, which expand beyond communication at the point of care and grant us a seat at the table for strategic initiatives that could drive significant incremental revenue opportunities.
Before moving on, I want everyone to know we understand the markets have been tumultuous. As an investor in the business myself, I believe it's important to delve into some high-level fundamentals. So everyone understands our position and why I'm more excited and bullish on our business than ever before.
First off, nearly 80% of our business comes from the 20 largest pharma manufacturers. Our clients remain in strong financial position today and have performed remarkably well throughout the pandemic.